Human TRAIL Platinum ELISA

Description: The human TRAIL ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human TRAIL.

TRAIL (TNF-related-apoptosis-inducing-ligand) was found to be a member of the TNF family which mediates cell death in a wide variety of malignant cell lines and primary tumor cells. TRAIL induces two different signals, cell death mediated by caspases and gene induction mediated by NFkappaB.

The cytotoxic ligand TRAIL interacts with five receptors, only two of which (TRAIL-R1 and R2) have a death domain.

TRAIL, which is ubiquitous expressed, exhibits very complex signalling and tumor-selective induction of apoptosis. TRAIL is involved in lymphatic neoplastic disorders and thyroid diseases, and the treatment of cancer like melanoma.

References: Schulze-Osthoff,K.; Ferrari,D.; Los,M.; Wesselborg,S.; Peter,M.E.. Apoptosis signaling by death receptors. Eur.J.Biochem. 1998;254:439-459. (Link)

Nagane,M.; Huang,H.J.; Cavenee,W.K.. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001;6:191-197. (Link)

Daniel,P.T.; Wieder,T.; Sturm,I.; Schulze-Osthoff,K.. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001;15:1022-1032. (Link)

Mitsiades,N.; Poulaki,V.; Mitsiades,C.S.; Koutras,D.A.; Chrousos,G.P.. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends Endocrinol.Metab 2001;12:384-390. (Link)

Golstein,P.. Cell death: TRAIL and its receptors. Curr.Biol. 1997;7:R750-R753. (Link)

Griffith,T.S.; Lynch,D.H.. TRAIL: a molecule with multiple receptors and control mechanisms. Curr.Opin.Immunol. 1998;10:559-563. (Link)

Greil,R.; Anether,G.; Johrer,K.; Tinhofer,I.. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools. J.Leukoc.Biol. 2003;74:311-330. (Link)

Bonavida,B.; Ng,C.P.; Jazirehi,A.; Schiller,G.; Mizutani,Y.. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review) 19. Int.J.Oncol. 1999;15:793-802. (Link)

Abe,K.; Kurakin,A.; Mohseni-Maybodi,M.; Kay,B.; Khosravi-Far,R.. The complexity of TNF-related apoptosis-inducing ligand. Ann.N.Y.Acad.Sci. 2000;926:52-63. (Link)

Held,J.; Schulze-Osthoff,K.. Potential and caveats of TRAIL in cancer therapy. Drug Resist.Updat. 2001;4:243-252. (Link)

Nguyen,T.; Thomas,W.; Zhang,X.D.; Gray,C.; Hersey,P.. Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma. Forum (Genova.) 2000;10:243-252. (Link)

Baetu,T.M.; Hiscott,J.. On the TRAIL to apoptosis. Cytokine Growth Factor Rev. 2002;13:199-207. (Link)